Article
Oncology
Michiel Stevens, Afroditi Nanou, Leon W. M. M. Terstappen, Christiane Driemel, Nikolas H. Stoecklein, Frank A. W. Coumans
Summary: This article explores the application of a deep learning-based segmentation method called StarDist in the enumeration of circulating tumor cells (CTC). Compared to the CellSearch system, StarDist can accurately segment CTC, especially in samples with high cell density.
Article
Oncology
Lucia Tombolan, Elisabetta Rossi, Andrea Binatti, Angelica Zin, Mariangela Manicone, Antonella Facchinetti, Silvia Lucchetta, Maria Carmen Affinita, Paolo Bonvini, Stefania Bortoluzzi, Rita Zamarchi, Gianni Bisogno
Summary: Liquid biopsy analysis is a powerful and noninvasive tool for uncovering molecular features and disease progression in pediatric rhabdomyosarcoma patients. The study found that patients with metastatic disease have a higher number of circulating tumor cells compared to those with localized disease, while the detection of disseminated tumor cells is independent of disease presentation. Liquid biopsy can also provide information about the molecular makeup of primary tumors.
MOLECULAR ONCOLOGY
(2022)
Article
Oncology
Jing-Jing Yu, Chang Shu, Hui-Yuan Yang, Zhao Huang, Ya-Ni Li, Ran Tao, Yue-Yue Chen, Qian Chen, Xiao-Ping Chen, Wei Xiao
Summary: This study found that CTC clusters are common in hepatocellular carcinoma patients and are associated with an aggressive phenotype. CTC clusters can be used as a biomarker to predict the prognosis of HCC patients at each stage of malignancy, providing evidence for formulating more precise treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Khrystany T. Isebia, Eshwari Dathathri, Noortje Verschoor, Afroditi Nanou, Anouk C. De Jong, Frank A. W. Coumans, Leon W. M. M. Terstappen, Jaco Kraan, John W. M. Martens, Ruchi Bansal, Martijn P. Lolkema
Summary: This study compared the composition of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in the blood of patients with metastatic castration-naive prostate cancer (CNPC) and metastatic castration-resistant prostate cancer (CRPC). The study found potential differences between these biomarkers in the two disease stages, with lower CTC and tdEV levels in CNPC compared to CRPC patients. Furthermore, the study observed a decline in CTC/tdEV numbers 6 months after androgen deprivation therapy (ADT).
Article
Multidisciplinary Sciences
Zhiyou Zong, Xinzhuo Liu, Zhuo Ye, Dingbin Liu
Summary: This study presents a double-switch pH-low insertion peptide (D-S pHLIP) system to selectively harvest cTME-EVs from the blood serum of tumor mouse models, overcoming the current technical challenges in cTME-EVs research. The cTME-EVs anchored by D-S pHLIP were magnetically enriched and analyzed with high-resolution mRNA sequencing, resulting in a significantly higher number of differentially expressed TME-related genes and hub genes compared to the gold-standard ultracentrifugation. This work could have a significant impact on TME research and clinical liquid biopsy for cancer.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Medicine, General & Internal
Nancy Huang, Katie J. Lee, Mitchell S. Stark
Summary: Melanoma is the leading cause of skin cancer deaths, and liquid biomarkers have advantages in monitoring tumor burden and heterogeneity. The only serological marker currently used, lactate dehydrogenase, is not specific or sensitive enough. This review summarizes the current research on liquid biomarkers, including circulating tumor cells, circulating tumor DNA, microRNA, and extracellular vesicles.
FRONTIERS IN MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Pai-Chi Teng, Vatche G. Agopian, Ting-Yi Lin, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang
Summary: Serum alpha-fetoprotein and radiologic imaging are commonly used tests for early diagnosis and treatment monitoring of hepatocellular carcinoma (HCC), but their accuracy is limited. Developing novel HCC biomarkers reflecting tumor biology is an unmet need. Circulating tumor cells (CTCs) have potential as a noninvasive biomarker for HCC, offering molecular and functional data that can reflect the underlying tumor.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Oncology
Eshwari Dathathri, Khrystany T. Isebia, Fikri Abali, Martijn P. Lolkema, John W. M. Martens, Leon W. M. M. Terstappen, Ruchi Bansal
Summary: Prostate cancer is a common male malignancy with diverse clinical presentations and challenging treatment options. Liquid biopsy provides opportunities for early diagnosis and personalized treatments.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Analytical
Fulai Li, Hengyi Xu, Yufen Zhao
Summary: As a new type of liquid biopsy, circulating tumor cell (CTC) detection and analysis offer the possibility of real-time monitoring of metastatic development, cancer recurrence, and therapeutic efficacy. The rarity and heterogeneity of CTCs present great challenges, and magnetic particle-based methods show promise for effective CTC capture. Progress has been made in utilizing magnetic particles to enhance CTC capture, which is crucial for cancer diagnosis and prognosis.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2021)
Review
Oncology
W. Yu, J. Hurley, D. Roberts, S. K. Chakrabortty, D. Enderle, M. Noerholm, X. O. Breakefield, J. K. Skog
Summary: Liquid biopsy in cancer research has seen significant progress, with efforts focused on utilizing circulating tumor cells, circulating tumor DNA, and extracellular vesicles like exosomes. Exosomes, as part of the intercellular communication system, carry tumor-derived materials and can serve as stable biomarkers for early detection and monitoring of cancer.
ANNALS OF ONCOLOGY
(2021)
Review
Medicine, Research & Experimental
Artur Slomka, Bingduo Wang, Tudor Mocan, Adelina Horhat, Arnulf G. Willms, Ingo G. H. Schmidt-Wolf, Christian P. Strassburg, Maria A. Gonzalez-Carmona, Veronika Lukacs-Kornek, Miroslaw T. Kornek
Summary: Liquid biopsies, as biomarkers in cancer diagnosis, have great potential but also limitations. This review focuses on comparing extracellular vesicles (EVs) and circulating tumor cells (CTCs) and discussing their similarities in characterization and quantification. While it is not concluded which is better between CTCs and EVs, the review provides reasons to intensify research on both.
Review
Immunology
Hiroyuki Oshiumi
Summary: Vaccination is the best way to prevent infectious diseases, but vaccine efficacy and adverse reactions vary among individuals. miRNAs in serum EVs can regulate immune responses and vaccine efficacy, such as miR-192 and miR-21. EV miRNAs can be used as tools to improve vaccine efficacy and predict immune responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Thorben Frundt, Johann von Felden, Jenny Krause, Asmus Heumann, Jun Li, Sabine Riethdorf, Klaus Pantel, Samuel Huber, Ansgar W. Lohse, Henning Wege, Kornelius Schulze
Summary: Cholangiocarcinoma is an aggressive tumor with a high rate of recurrence. We found that circulating tumor cells may serve as biomarkers for preoperative assessment of micrometastases and are associated with significantly impaired survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Marta Lombardi, Martina Gabrielli, Elena Adinolfi, Claudia Verderio
Summary: ATP serves as a danger signal in the immune response by activating P2X and P2Y receptors to promote inflammation, with the P2X7 receptor being a critical player. ATP stimulation leads to cell proliferation, inflammasome activation, and extracellular vesicle release, which can transfer molecules to target cells. This review discusses the role of ATP in the biogenesis and dynamics of extracellular vesicles, highlighting their important functions in physiology and pathophysiology.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Robert H. Eibl, Markus Schneemann
Summary: Liquid biopsy has shown promising potential in the diagnosis, prognosis, monitoring, and therapy of brain tumors, with the ability to monitor tumor progression and treatment response based on genetic profiling. However, challenges and disappointments also exist, highlighting the urgent need for suitable biomarkers and standards to enhance modern clinical management of brain tumor patients.
Review
Oncology
D. Araujo, A. Greystoke, S. Bates, A. Bayle, E. Calvo, L. Castelo-Branco, J. de Bono, A. Drilon, E. Garralda, P. Ivy, O. Kholmanskikh, I. Melero, G. Pentheroudakis, J. Petrie, R. Plummer, S. Ponce, S. Postel-Vinay, L. Siu, A. Spreafico, A. Stathis, N. Steeghs, C. Yap, T. A. Yap, M. Ratain, L. Seymour
Summary: In 2021, the FDA Oncology Center of Excellence launched Project Optimus to optimize dosage for oncology drugs. The MDICT Taskforce reviewed and discussed dosage optimization for oncology trials, providing recommendations for trial design and a practical guide for phase I trials. The aim is to improve dosage selection in early clinical trials of new anticancer treatments and ultimately enhance patient outcomes.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Summary: This study evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying BRCA1, BRCA2, and ATM alterations in patients with metastatic castration-resistant prostate cancer. The results showed that ctDNA detection can complement tissue testing and serve as a valuable alternative for patients with no or insufficient tissue for genomic analyses.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yuksel Urun, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain
Summary: The purpose of this study was to evaluate the use of ctDNA testing as an alternative method to identify mCRPC patients with HRR gene alterations who may benefit from olaparib treatment. The results showed that ctDNA testing can be a suitable alternative when tissue testing is not feasible or has failed.
CLINICAL CANCER RESEARCH
(2023)
Article
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhofer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Summary: This study evaluated the efficacy and safety of pembrolizumab plus olaparib in previously treated patients with metastatic castration-resistant prostate cancer. The results demonstrated antitumor activity and expected safety of this combination therapy in patients.
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Editorial Material
Urology & Nephrology
Khobe Chandran, Rafael Grochot, Maria de Los Dolores Fenor De La Maza, Wei Yuan, Bora Gurel, Susana Miranda, Alec Paschalis, Ruth Riisnaes, Ines Figueiredo, Denisa Bogdan, Adam Sharp, Suzanne Carreira, Johann S. de Bono
Correction
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhoefer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Article
Biochemistry & Molecular Biology
Eliot B. Blatt, Karla Parra, Antje Neeb, Lorenzo Buroni, Denisa Bogdan, Wei Yuan, Yunpeng Gao, Collin Gilbreath, Alec Paschalis, Suzanne Carreira, Ralph J. DeBerardinis, Ram S. Mani, Johann S. de Bono, Ganesh V. Raj
Summary: Therapy resistance to enzalutamide, a second-generation androgen receptor antagonist, is common in advanced prostate cancer (PCa) patients. This resistance is associated with higher levels of reactive oxygen species (ROS) and enhanced glutamine metabolism. Inhibiting glutamine metabolism or targeting antioxidant pathways can block the growth of enzalutamide-resistant PCa cells.
Article
Medicine, General & Internal
Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander, Andrew Kightley, Jeffry Evans, Shing Lee, Alun Bedding, Sally Hopewell, Khadija Rantell, Rong Liu, An-Wen Chan, Johann De Bono, Christina Yap
Summary: The DEFINE study aims to improve the transparency, completeness, reproducibility, and interpretation of EPDF trial protocols (SPIRIT-DEFINE) and their reports (CONSORT-DEFINE). An extensive review of published trials and consultation with international experts will be conducted to refine the guidelines. The final version of the guidelines will be determined through a modified Delphi process and an international consensus meeting.
Article
Medicine, General & Internal
Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Summary: This study aims to develop guidelines for early phase dose-finding trials through reviewing published trial reports and conducting a Delphi process. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines were developed, and a lay summary toolkit was created through patient and public involvement.
Article
Oncology
Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Stephen J. Pettitt, Nan Shao, Diana Zatreanu, Jessica Frankum, Ilirjana Bajrami, Rachel Brough, Dragomir B. Krastev, Theodoros I. Roumeliotis, Jyoti S. Choudhary, Sonja Lorenz, Alistair Rust, Johann S. de Bono, Timothy A. Yap, Andrew N. J. Tutt, Christopher J. Lord
Summary: Reduced expression of HUWE1 leads to increased levels of BRCA1- increment 11q and PARPi resistance. This effect is specific to cells able to express BRCA1- increment 11q and is not seen in other BRCA1 or BRCA2 mutant cells. HUWE1 silencing also restores RAD51 nuclear foci and platinum salt resistance, indicating its potential as a biomarker for PARPi resistance in future clinical trials.
Article
Medicine, General & Internal
Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J. Weir
Summary: The CONSORT-DEFINE guidance provides comprehensive reporting guidelines for early phase dose-finding trials, aiming to improve the quality of reporting and facilitate result interpretation.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Ashwin Roy, Ravi Vijapurapu, Tarekegn Geberhiwot, Joseph De Bono, Adrian Warfield, Richard Steeds, Derralynn Hughes, James Moon, Polyvios Demetriades, Peter Woolfson
Article
Oncology
Johann S. de Bono, Jeffrey R. Harris, Saskia M. Burm, Adriaan Vanderstichele, Mischa A. Houtkamp, Saida Aarass, Ruth Riisnaes, Ines Figueiredo, Daniel Nava Rodrigues, Rossitza Christova, Siel Olbrecht, Hans W. M. Niessen, Sigrid R. Ruuls, Danita H. Schuurhuis, Jeroen J. Lammerts van Bueren, Esther C. W. Breij, Ignace Vergote
Summary: This study compares the expression of tissue factor (TF) across various solid tumor types using immunohistochemistry. The results show that TF is expressed in multiple solid cancers and remains present during tumor dissemination and treatment.